Aminoglycosides and polymyxins;Aminoglucósidos y polimixinas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 3, 2009, Pages 178-188

  Molina, José ^a   Cordero, Elisa ^a   Palomino, Julián ^a   Pachón, Jerónimo ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Aminoglycosides; Multi drug resistant gram negative bacilli; Polymyxins

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; COLISTIN; DIBEKACIN; GENTAMICIN; ISEPAMICIN; KANAMYCIN; NEOMYCIN; NETILMICIN; PAROMOMYCIN; POLYMYXIN; PROMIXIN; SISOMICIN; STREPTOMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS;

EID: 62949110736     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.02.001     Document Type: Article

References (50)

1. S. Shakil, R. Khan, R. Zarrilli, and A.U. Khan Aminoglycosides versus bacteria - a description of the action, resistance mechanism, and nosocomial battleground J Biomed Sci 15 2008 5 14
2. Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the aminoglycosides? Int J Antimicrob Agents. En prensa 2009.
3. G.L. Drusano, P.G. Ambrose, S.M. Bhavnani, J.S. Bertino, A.N. Nafziger, and A. Louie Back to the future: using aminoglycosides again and how to dose them optimally Clin Infect Dis 45 2007 753 760
4. Gilbert DN. Aminoglycosides. En: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier-Churchill Livingstone; 2005. p. 307-36.
5. F. Pea, P. Viale, and M. Furlanut Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability Clin Pharmacokinet 44 2005 1009 1034
6. J.A. Roberts, and J. Lipman Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis Clin Pharmacokinet 45 2006 755 773
7. R.N. Jones, H.S. Sader, and M.L. Beach Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001) Int J Antimicrob Agents 22 2003 551 556
8. H.S. Sader, D.J. Biedenbach, and R.N. Jones Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001) Diagn Microbiol Infect Dis 47 2003 361 364
9. M. Galimand, P. Courvalin, and T. Lambert Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation Antimicrob Agents Chemother 47 2003 2565 2571
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth Informational Supplement. Document M100-S17. 2007.
11. H.S. Sader, J.M. Streit, T.R. Fritsche, and R.N. Jones Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004) Clin Microbiol Infect 12 2006 844 852
12. M.E. Falagas, D.K. Matthaiou, and I.A. Bliziotis The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials J Antimicrob Chemother 57 2006 639 647
13. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Betalactámico versus tratamiento de combinación de betalactá mico+aminoglucósido en pacientes oncológicos con neutropenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
14. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Monoterapia con betalactámicos versus combinación de betalactámico y aminoglucósido para el tratamiento de la sepsis (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
15. M.E. Falagas, D.K. Matthaiou, E.A. Karveli, and G. Peppas Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections Aliment Pharmacol Ther 25 2007 537 556
16. L. Vidal, A. Gafter-Gvili, S. Borok, A. Fraser, L. Leibovici, and M. Paul Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials J Antimicrob Chemother 60 2007 247 257
17. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
18. Smyth AR, Tan KH. Dosis diaria única versus dosis diaria múltiple de aminoglucósidos intravenosos para la fibrosis quística (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
19. R.B. Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 121 2002 55 63
20. de Alarcón A, Gálvez J, Reguera JM, Ruiz J, Lomas JM. Documento de consenso de la Sociedad Andaluza de Enfermedades Infecciosas sobre el tratamiento y profilaxis de la endocarditis infecciosa. Disponible en: http://saei.org/hemero/consensos/endocarditis-infecciosas.html.
21. L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, A.F. Bolger, and M.E. Levison Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation 111 2005 394 434
22. L. Leibovici, L. Vidal, and M. Paul Aminoglycoside drugs in clinical practice: an evidence-based approach J Antimicrob Chemother 63 2009 246 251
23. J. Fernández-Gallego, A. Alonso, S. Sujan, and E. Gutiérrez Prophylaxis with gentamycin reduces bacterial infection morbidity and mortality caused by permanent tunneled central venous catheter Nefrologia 27 2007 228 229
24. Q. Cui, W.M. Mihalko, J.S. Shields, M. Ries, and K.J. Saleh Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty J Bone Joint Surg Am 89 2007 871 882
25. P.A. Gross, T.L. Barrett, E.P. Dellinger, P.J. Krause, W.J. Martone, and J.E. McGowan Purpose of quality standards for infectious diseases. Infectious Diseases Society of America Clin Infect Dis 18 1994 421
26. D.N. Fisman, and K.M. Kaye Once-daily dosing of aminoglycoside antibiotics Infect Dis Clin North Am 14 2000 475 487
27. F. Álvarez-Lerma, P. Olaechea, S. Grau, M. Marín, A. Domínguez, and J. Martínez-Lanao Recommendations for antibiotic monitoring in ICU patients Enferm Infecc Microbiol Clin 26 2008 230 239
28. D. Beauchamp, and G. Labrecque Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care 7 2001 401 408
29. O.W. Guthrie Aminoglycoside induced ototoxicity Toxicology 249 2008 91 96
30. T.R. Pasquale, and J.S. Tan Nonantimicrobial effects of antibacterial agents Clin Infect Dis 40 2005 127 135
31. M.E. Falagas, and S.K. Kasiakou Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections Clin Infect Dis 40 2005 1333 1341
32. D. Landman, C. Georgescu, D.A. Martin, and J. Quale Polymyxins revisited Clin Microbiol Rev 21 2008 449 465
33. Agencia Española del Medicamento. Medicamentos autorizados en España para uso humano. Disponible en: www.agemed.es.
34. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, and C.R. Rayner Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect Dis 6 2006 589 601
35. A.C. Gales, R.N. Jones, and H.S. Sader Global assessment of the antimicrobial activity of polymyxin B against 54.731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) Clin Microbiol Infect 12 2006 315 321
36. R.J. Owen, J. Li, R.L. Nation, and D. Spelman In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates J Antimicrob Chemother 59 2007 473 477
37. A. Poudyal, B.P. Howden, J.M. Bell, W. Gao, R.J. Owen, and J.D. Turnidge In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae J Antimicrob Chemother 62 2008 1311 1318
38. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect. En prensa 2009.
39. A.L. Kwa, V.H. Tam, and M.E. Falagas Polymyxins: a review of the current status including recent developments Ann Acad Med Singapore 37 2008 870 883
40. N. Petrosillo, E. Ioannidou, and M.E. Falagas Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies Clin Microbiol Infect 14 2008 816 827
41. A.L. Kwa, T.P. Lim, J.G. Low, J. Hou, A. Kurup, and R.A. Prince Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections Diagn Microbiol Infect Dis 60 2008 163 167
42. J. Li, K. Coulthard, R. Milne, R.L. Nation, S. Conway, and D. Peckham Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis J Antimicrob Chemother 52 2003 987 992
43. M.E. Falagas, I.A. Bliziotis, and V.H. Tam Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence Int J Antimicrob Agents 29 2007 9 25
44. R.L. Trotman, J.C. Williamson, D.M. Shoemaker, and W.L. Salzer Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy Clin Infect Dis 41 2005 1159 1166
45. V.H. Tam, A.N. Schilling, G. Vo, S. Kabbara, A.L. Kwa, and N.P. Wiederhold Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa Antimicrob Agents Chemother 49 2005 3624 3630
46. V. Pintado, L.G. San Miguel, F. Grill, B. Mejía, J. Cobo, and J. Fortún Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria J Infect 56 2008 185 190
47. M.E. Falagas, S.K. Kasiakou, S. Tsiodras, and A. Michalopoulos The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature Clin Med Res 4 2006 138 146
48. M.E. Falagas, I.I. Siempos, I.A. Bliziotis, and A. Michalopoulos Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials Crit Care 10 2006 R123
49. M.E. Falagas, and P.I. Rafailidis When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach Shock 27 2007 605 609
50. M.E. Falagas, and S.K. Kasiakou Toxicity of polymyxins: a systematic review of the evidence from old and recent studies Crit Care 10 2006 R27